Alvotech filings document a foreign private issuer focused on biosimilar medicine development and manufacturing. Its Form 6-K reports furnish press releases, earnings materials, business updates and exhibits that are incorporated by reference into registration statements on Forms F-3, F-3ASR and S-8 where applicable.
The disclosure record covers financial results, the Form 20-F annual reporting framework, FDA and cGMP matters involving the Reykjavik manufacturing facility, biosimilar clinical and pharmacokinetic updates, supply and commercialization agreements, patent-settlement disclosures, executive-team changes and notifications of manager-related share transactions reported through Luxembourg CSSF forms. These filings also document governance, capital-market registrations and recurring regulatory topics for Alvotech’s biosimilar portfolio.
Alvotech submitted a Form 6-K as a foreign private issuer to furnish a recent press release to investors. The filing states that, on November 12, 2025, the company issued a press release announcing its earnings for the first nine months of 2025 and providing a business update. The Form 6-K also clarifies that, except for the attached press release, the report is incorporated by reference into several existing Alvotech shelf and employee share plan registration statements, which means those registrations now formally include this new information.
Alvotech furnished a Form 6-K noting that a justice of the UK High Court rejected an injunction request from Regeneron Pharmaceuticals, joined by Bayer, relating to manufacturing activities at Alvotech’s UK contract manufacturing organization for its Eylea biosimilar candidate, AVT06. The company attached a press release as Exhibit 99.1.
The Form 6-K, excluding Exhibit 99.1, is incorporated by reference into Alvotech’s registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111 and 333-281684), its Form F-3ASR (File No. 333-289006), and its Form S-8 (File No. 333-266881). Exhibit 99.1 is furnished, not filed.
Alvotech filed a Form 6-K reporting that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved its biosimilar to Simponi (golimumab), marketed as Gobivaz. The company furnished a press release announcing the approval as Exhibit 99.1.
The report states that this Form 6-K, excluding Exhibit 99.1, is incorporated by reference into Alvotech’s registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111 and 333-281684), its Form F-3ASR (File No. 333-289006), and its Form S-8 (File No. 333-266881). Exhibit 99.1 is furnished, not filed, under the Exchange Act.
Alvotech filed a Form 6-K noting that the U.S. Food and Drug Administration issued a complete response letter for its AVT05 Biologics License Application, covering prefilled syringe and autoinjector presentations of a proposed biosimilar to Simponi (golimumab). Following the letter, the company has reevaluated its outlook for 2025. The report incorporates the 6-K (excluding the press release) by reference into certain registration statements. The related press release, furnished as Exhibit 99.1, is not deemed filed under the Exchange Act.
Alvotech filed a Form 6-K noting organizational changes and furnishing a press release about its commercial team, including the departure of Chief Commercial Officer Anil Okay. The report states that, excluding Exhibit 99.1, this Form 6-K is incorporated by reference into the company’s registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111, 333-281684), its F-3ASR (File No. 333-289006), and its S-8 (File No. 333-266881). Exhibit 99.1—the press release dated October 22, 2025—is furnished and not deemed filed, and it is not incorporated by reference under the Securities Act or Exchange Act.
Alvotech announced that the European Medicines Agency has accepted a Marketing Authorization Application for AVT23, a proposed biosimilar to Xolair®. The company developed AVT23 with Kashiv BioSciences LLC and has licensed commercialization rights to Advanz Pharma Holdco Limited across the European Economic Area, the UK, Switzerland, Canada, Australia and New Zealand.
This filing notifies investors that regulatory review will proceed for a late‑stage biosimilar candidate and clarifies the commercialization partner and covered territories, which could affect future revenue timing and market access if authorization is granted.
Alvotech reported regulatory progress for multiple biosimilars in September 2025. Fuji Pharma received Japanese marketing authorization for three Alvotech-developed products: AVT03 (referencing Xgeva/denosumab), AVT05 (referencing Simponi/golimumab) and AVT06 (referencing Eylea/aflibercept). Separately, the European Medicines Agency's CHMP adopted positive opinions recommending approval in the European Economic Area for AVT03 (referencing Prolia/Xgeva) and AVT05 (referencing Simponi); final European Commission decisions are pending. The company furnished press releases as Exhibits 99.1–99.3, which are provided for incorporation by reference but are not being "filed" for certain Exchange Act liabilities.
Alvotech filed a Form 6-K that incorporates by reference three exhibits tied to its public filings: unaudited condensed consolidated interim financial statements for the six months ended June 30, 2025 and June 30, 2024 (Exhibit 99.1), Management's Discussion and Analysis (Exhibit 99.2) and an earnings release for the six months ended June 30, 2025 (Exhibit 99.3).
The company also announced a business update conference call and live webcast on Thursday, August 14 at 8:00 am ET, with a replay available on its website for 90 days. The report includes a standard cautionary note that forward-looking statements involve risks and may differ materially from actual results.